拜瑞妥说明书

Xarelto Instructions

Drug name: Generic name: Rivaroxaban tablets

Product name: Rivaroxaban tablets, Xarelto

Pinyin full code: LiFaShaBanPian, BaiRuiTuo

Main ingredients: The main ingredient of this product is rivaroxaban.

Indications/Function Indications: 1. For adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE). 2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism. 

How to take: The recommended dose is 10 mg of Xarelto taken orally, once a day. If the wound has stopped bleeding, the first medication should be administered between 6-10 hours after surgery. The length of treatment is determined by each patient's risk of VTE, i.e. by the type of orthopedic surgery the patient has undergone. For patients undergoing major hip surgery, a recommended course of treatment is 5 weeks. For patients undergoing major knee surgery, a recommended course of treatment is 2 weeks. If a dose is missed, the patient should take Xarelto immediately and continue taking the medication once a day the next day. Patients can take Xarelto with a meal or alone.

Notes: 1. Bleeding risk: As detailed below, some subgroups of patients have a higher risk of bleeding. After initiation of treatment, these patients should be monitored closely for signs of bleeding complications. This can be accomplished by regular physical examination of the patient, close observation of surgical wound drainage, and regular determination of hemoglobin. Any unexplained decrease in hemoglobin or blood pressure should prompt a search for the site of bleeding. 2. Renal damage: In patients with severe renal impairment (creatinine clearance <30 mL/min), the plasma concentration of Xarelto may be significantly increased, leading to an increased risk of bleeding. Xarelto is not recommended for patients with creatinine clearance <15 mL/min. Rivaroxaban should be used with caution in patients with creatinine clearance 15-29 mL/min. Rivaroxaban should be used with caution in patients with moderate renal impairment (creatinine clearance 30-49 mL/min) when used concomitantly with other drugs that may increase the plasma concentration of Xarelto. 3. Liver damage: In cirrhotic patients with moderate liver damage (Child Pugh category B), the plasma concentration of Xarelto may be significantly increased, leading to an increased risk of bleeding. Xarelto is contraindicated in patients with liver disease associated with coagulation abnormalities and clinically relevant risk of bleeding. Rivaroxaban can be used with caution in patients with cirrhosis who have moderate hepatic impairment (Child Pugh category B) and are not accompanied by coagulation abnormalities. 4. Interactions with other drugs: in azole-antifungal agents (such as ketoconazole, itraconazole, voriconazole and posaconazole). Please read the instructions carefully and use it as directed by your doctor.

Adverse reactions: Common adverse reactions of Xarelto include nausea, increased GGT and increased aminotransferases. Adverse effects should be explained in the context of surgery. Due to its pharmacological mode of action, Xarelto may cause an increased risk of latent or overt bleeding in some tissues or organs, possibly resulting in posthemorrhagic anemia. The signs, symptoms, and severity of bleeding (including possible fatal consequences) will vary depending on the location, extent, or extent of the bleeding. The risk of bleeding may be increased in certain patient groups, such as patients with uncontrolled severe arterial hypertension and/or patients receiving concomitant medications that affect hemostasis. Hemorrhagic complications may manifest as weakness, weakness, pallor, dizziness, headache, or unexplained swelling. Therefore, the possibility of bleeding should be considered when evaluating patients taking anticoagulants.

The above is the content of the Xarelto instruction manual, I hope it can help you!